Investigation of Programmed Cell Death-1 (PD-1) Gene Variations at Positions PD1.3 and PD1.5 in Iranian Patients with Non-small Cell Lung Cancer
(ندگان)پدیدآور
Piredelkhosh, ZahraKazemi, TohidHaghshenas, Mohammad RezaGhayumi, Mohammad AliErfani, Nasrollah
نوع مدرک
TextOriginal Article
زبان مدرک
Englishچکیده
Background: Tumor cells express PD-1 ligands to bind PD-1 on immune cells and escape immune responses. In the present study, we aimed to investigate whether single nucleotide polymorphisms at positions PD1.3 (+7146, rs11568821) G/A, and PD1.5 (+7785 C/T, rs2227981) may be considered risk factors for susceptibility to nonsmall cell lung cancer in the Iranian population. Methods: This study enrolled 206 histopathologically confirmed lung cancer patients and 173 age/sex matched healthy controls. We performed PCR-RFLP to determine the genotypes of the extracted genomic DNA.Results: The frequencies of PD1.3 GG, GA and AA genotypes were 171 (83%), 31 (15%) and 4 (1.9%) out of 206 patients, and 144 (83.2%), 26 (15%), and 3 (1.7%) out of 173 controls, respectively. The frequencies of PD1.5 CC, CT and TT genotypes were 78 (37.9%), 100 (48.5%), and 28 (13.6%) in patients, and 60 (34.7%), 89 (51.4%), and 24 (13.9%) in controls. There were no significant differences in genotype analysis between patients and controls at positions PD1.3 (P=0.98) or PD1.5 (P=0.80). No significant differences existed in the frequencies of alleles and haplotypes between the two groups (P>0.05).Conclusion: Our data have indicated no association between PD1.3 (+7146) G/A and PD1.5 (+7785) C/T with susceptibility to non-small cell lung cancer. Investigation of other PD1 genetic variations and emerged haplotypes are required to completely define the role of PD1 genetic variations in susceptibility to lung cancer.
شماره نشریه
1تاریخ نشر
2018-01-011396-10-11
ناشر
Shiraz University of Medical Sciencesسازمان پدید آورنده
Immunology Research Center, Tabriz University of Medical Sciences, Tabriz, IranImmunology Research Center, Tabriz University of Medical Sciences, Tabriz, Iran
Cancer Immunology Group, Shiraz Institute for Cancer Research, School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran
Department of Internal Medicine, Faghihi Hospital, Shiraz University of Medical Sciences, Shiraz, Iran
Department of Internal Medicine, Faghihi Hospital, Shiraz University of Medical Sciences, Shiraz, Iran
شاپا
2008-67092008-6687



